Rosuvastatin Calcium Tablet, Film Coated
NDC Package 71209-045-04
Package Information
Rosuvastatin Calcium tablets is rosuvastatin tablets are indicated:To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events. This formulation utilizes a tablet, film coated delivery system. Marketed by Cadila Pharmaceuticals Limited, this product is identified by NDC 71209-045 and is authorized under FDA application ANDA207453.
Identification & Billing
- RxCUI: 859419 - rosuvastatin calcium 40 MG Oral Tablet
- RxCUI: 859424 - rosuvastatin calcium 5 MG Oral Tablet
- RxCUI: 859747 - rosuvastatin calcium 10 MG Oral Tablet
- RxCUI: 859751 - rosuvastatin calcium 20 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71209 - Cadila Pharmaceuticals Limited
- 71209-045 - Rosuvastatin Calcium
- 71209-045-04 - 90 TABLET, FILM COATED in 1 BOTTLE
- 71209-045 - Rosuvastatin Calcium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71209-045-04 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Rosuvastatin Calcium, a human prescription drug labeled by Cadila Pharmaceuticals Limited. This tablet, film coated is formulated for oral use and contains rosuvastatin calcium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cadila Pharmaceuticals Limited on March 24, 2017. The current certification is valid through December 31, 2027.
How is this Cadila Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71209004504. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.